GLUE
Price
$16.56
Change
-$0.67 (-3.89%)
Updated
Dec 11 closing price
Capitalization
1.08B
90 days until earnings call
Intraday BUY SELL Signals
KYMR
Price
$90.51
Change
+$2.70 (+3.07%)
Updated
Dec 12, 11:46 AM (EDT)
Capitalization
7.02B
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GLUE vs KYMR

Header iconGLUE vs KYMR Comparison
Open Charts GLUE vs KYMRBanner chart's image
Monte Rosa Therapeutics
Price$16.56
Change-$0.67 (-3.89%)
Volume$632.82K
Capitalization1.08B
Kymera Therapeutics
Price$90.51
Change+$2.70 (+3.07%)
Volume$300
Capitalization7.02B
GLUE vs KYMR Comparison Chart in %
View a ticker or compare two or three
VS
GLUE vs. KYMR commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Buy and KYMR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (GLUE: $16.56 vs. KYMR: $87.81)
Brand notoriety: GLUE and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 59% vs. KYMR: 147%
Market capitalization -- GLUE: $1.08B vs. KYMR: $7.02B
GLUE [@Biotechnology] is valued at $1.08B. KYMR’s [@Biotechnology] market capitalization is $7.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 1 FA rating(s) are green whileKYMR’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 1 green, 4 red.
  • KYMR’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 2 TA indicator(s) are bullish while KYMR’s TA Score has 3 bullish TA indicator(s).

  • GLUE’s TA Score: 2 bullish, 4 bearish.
  • KYMR’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, KYMR is a better buy in the short-term than GLUE.

Price Growth

GLUE (@Biotechnology) experienced а -4.06% price change this week, while KYMR (@Biotechnology) price change was +32.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

GLUE is expected to report earnings on Mar 12, 2026.

KYMR is expected to report earnings on Feb 19, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($7.03B) has a higher market cap than GLUE($1.08B). GLUE YTD gains are higher at: 138.617 vs. KYMR (118.270). GLUE has higher annual earnings (EBITDA): 23.3M vs. KYMR (-267.03M). KYMR has more cash in the bank: 665M vs. GLUE (291M). GLUE has less debt than KYMR: GLUE (41.1M) vs KYMR (85.7M). GLUE has higher revenues than KYMR: GLUE (178M) vs KYMR (44.7M).
GLUEKYMRGLUE / KYMR
Capitalization1.08B7.03B15%
EBITDA23.3M-267.03M-9%
Gain YTD138.617118.270117%
P/E Ratio51.75N/A-
Revenue178M44.7M398%
Total Cash291M665M44%
Total Debt41.1M85.7M48%
TECHNICAL ANALYSIS
Technical Analysis
GLUEKYMR
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
89%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
GLUE
Daily Signal:
Gain/Loss:
KYMR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWSZX77.870.79
+1.02%
Hotchkis & Wiley Small Cap Value Z
TANDX37.470.36
+0.97%
Tandem Fund
JGICX70.800.37
+0.53%
Janus Henderson Growth And Income C
PQIPX14.480.03
+0.21%
PIMCO Dividend and Income I2
IYHIX5.95N/A
N/A
Nomura High Income Fund Class R

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with KURA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-3.89%
KURA - GLUE
46%
Loosely correlated
-2.61%
IMNM - GLUE
46%
Loosely correlated
-3.99%
XNCR - GLUE
41%
Loosely correlated
-0.58%
KYMR - GLUE
40%
Loosely correlated
-2.31%
NRIX - GLUE
40%
Loosely correlated
-2.75%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with NRIX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
-2.31%
NRIX - KYMR
62%
Loosely correlated
-2.75%
WVE - KYMR
55%
Loosely correlated
-17.20%
OCUL - KYMR
54%
Loosely correlated
-4.80%
VERA - KYMR
52%
Loosely correlated
+3.79%
GPCR - KYMR
51%
Loosely correlated
-2.18%
More